ODAC meeting on Peg-IFN postponed

Schering-Plough (NYSE:SGP) said FDA's Oncologic Drugs Advisory Committee postponed its March 12 review of an sBLA for Peg-IFN peginterferon alfa-2b for the adjuvant treatment of stage III melanoma. Th...